The coxibs, selective inhibitors of cyclooxygenase-2.
By S. Rich. New England Journal of Medicine, 2001
630 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/01a60ca3cedbe44803d6a1dbed6a7ca6f5e2306c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Maria Grazia Perrone
- Clifford J. Woolf
- Peter Libby
- J. Scholz
- A. Scilimati
- L. Simone
- Paola Vitale
- T. Warner
Citations in the corpus
- Selective COX-1 inhibition: A therapeutic target to be reconsidered. (2010, methodology): “The role of COX-1 in the humans for platelet activation was enlightened by the use of low-doses of aspirin [10], a preferential inhibitor of platelet COX-1, whereas the action of COX-1 in protecting the gastrointestinal tract was demonstrated indirectly using coxibs which spare COX-1 [6].”
- Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition (2004, background): “The IP receptor couples to the Gs protein and increases intracellular cAMP concentrations, thus antagonizing the contractile agonists and inhibiting the mitogen-activated protein kinase pathway (FitzGerald and Patrono, 2001).”
- Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic (2004, background): “In healthy normal individuals, both celecoxib and rofecoxib reduce PGI2 production, as determined by the measurement of urinary metabolites (7).”
- Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. (2008, background): “of PG’s, thromboxanes (TxA) and other eicosanoids (11, 26, 27).”
- Can we conquer pain? (2002, background): “One great success in modern pain pharmacology has been the introduction of Cox2-specific inhibitors, but rather than possessing improved efficacy, these drugs produce less gastric and bleeding side effects by not inhibiting Cox1 (ref”
- Stabilization of atherosclerotic plaques: New mechanisms and clinical targets (2002, background): “The use of selective inhibitors of the inflammatory isoform of cyclooxygenase, an enzyme overexpressed in atheroma, might prove complex: These agents might block prostacyclin production but not that of thromboxane, theoretically enhancing thrombosi”